Bio-Techne reported flat organic growth in its fiscal Q2, with strength in large pharma and protein analysis instruments offset by weakness in emerging biotech and academia. Management guided for continued stabilization and gradual recovery, maintaining its operating margin expansion target. Total revenue of $295.9M, flat YoY; adjusted EPS of $0.46, up 10%.
Bio-Techne reported flat organic growth in its fiscal Q2, with strength in large pharma and protein analysis instruments offset by weakness in emerging biotech and academia. Management guided for continued stabilization and gradual recovery, maintaining its operating margin expansion target. Total revenue of $295.9M, flat YoY; adjusted EPS of $0.46, up 10%.
Management acknowledges ongoing challenges but highlights stabilization and improving end-market indicators, expressing confidence in gradual recovery.
Total revenue of $295.9M, flat YoY; adjusted EPS of $0.46, up 10%.
Protein Sciences declined 1% organically; Diagnostics & Spatial Biology grew 3% organically.
Two largest cell therapy customers paused GMP reagent orders after FDA fast-track designation, creating a headwind.
Management views AI as an enabler for customers and itself, expecting AI to drive demand for more complex molecules and ingredients, which plays into the company's strengths.
Underlying organic growth excluding customer headwinds improves to 3% from 1%. Management acknowledges ongoing challenges but highlights stabilization and improving end-market indicators, expressing confidence in gradual recovery.
Management acknowledges ongoing challenges but highlights stabilization and improving end-market indicators, expressing confidence in gradual recovery.
“These designations accelerate clinical timelines but reduce near-term reagent demand... a temporary pause in GMP reagent purchases.”
“COMET's automated multi-omic capabilities... delivered nearly 40% growth in bookings, marking the second consecutive quarter of strong booking activity.”
“As you know, biotech funding rebounded meaningfully in the second half of calendar 2025, positioning this end market for improvement going forward.”
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| Op margin | FY2026 | 100% | 100% | MAINTAINED |
| Revenue | FY2026 Q3 | 0% | 0% | GUIDED |